FDA OKs Unfors' PSD

TriMed Staff | | Health Imaging | Screening
Unfors has been granted 510(k) FDA approval for the Unfors PSD, Patient Skin Dosimeter.

Designed for real-time direct patient measurements of skin dose, the Unfors PSD is used during long fluoroscopic and CT procedures to prevent excessive dose usage and consequential lesions on patients.

The Unfors PSD consists of up to four unique, small sensors connected to a display unit. The small sensors can be placed anywhere on the body and will leave a minimal footprint on the X-ray image. Each sensor will display accumulated dose and exposure time. Audible and visual alarms are triggered when selected or critical dose limits are exceeded, said Unfors.

TriMed Staff

Related Content

Rising rates of interval breast cancers have experts calling for more risk-based screenings
Rates of breast cancer diagnosis, death expected to climb in coming decades
AI quantifies breast arterial calcifications on mammograms
AI 'not safe' to be implemented as a solo reader for breast cancer screening exams
American College of Radiology announces significant expansion of Lung Cancer Screening Registry
AI beats standard regression models at predicting lung cancer risk

Around the web

Cardiovascular Business
GE HealthCare launches new cardiac CT scanner with advanced AI capabilities

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Cardiovascular Business
Bracco updates HeartSee coronary flow capacity software with new diagnostic features

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

Cardiovascular Business
Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.